

PHA 2005 (3167/6Z/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1617
Serial No. 09/857,994
Filed October 5, 2001
Confirmation No. 4028
For METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE
TREATMENT OF NEOPLASIA

February 18, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.


In preparation of this Supplemental Information Disclosure Statement, Applicants determined that approximately 1,000 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this

PHA 2005 (3167/6Z/US)
PATENT

Supplemental Information Disclosure Statement. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/msc
*Enclosures

Mail Stop AF
Express Mail Label No. EV 416453092 US

PTO/SB/08A FEB 18 2004 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	09/857,994	
				Filing Date	October 5, 2001	
				Confirmation Number	4028	
				First Named Inventor	John P. McKearn et al.	
				Group Art Unit	1617	
Examiner Name	San-ming R. Hui					
Sheet	1	of	2	Attorney Docket No.	PHA 2005 (3167/6Z/US)	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	282.	6,077,850		Carter et al.	06-20-2000		
	283.	6,087,392		Reiter	07-11-2000		
	284.	6,110,964		Robinson	08-29-2000		
	285.	6,114,361		Robinson et al.	09-05-2000		
	286.	6,156,798		Reiter	12-05-2000		
	287.	6,214,870	B1	McClure et al.	04-10-2001		
	288.	6,277,878	B1	Nakao et al.	08-21-2001		
	289.	6,294,558	B1	Ando et al.	09-25-2001		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	290.	EP	1 081 137	A1	Pfizer Products Inc.	03-07-2001	
	291.	EP	1 088 550	A1	Pfizer Products Inc.	04-04-2001	
	292.	EP	1 104 759	A1	Pfizer Products Inc.	06-06-2001	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/857,994
				Filing Date	October 5, 2001
				Confirmation Number	4028
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1617
Examiner Name	San-ming R. Hui				
Sheet	2	of	2	Attorney Docket No.	PHA 2005 (3167/6Z/US)

	293.	EP	1 104 760	A1	Pfizer Products Inc.	06-06-2001	
	294.	EP	1 134 215	A1	Pfizer Products Inc.	09-19-2001	
	295.	EP	1 138 680	A1	Pfizer Products Inc.	10-04-2001	
	296.	WO	97/48685	A1	Glaxo Group Limited	12-24-1997	
	297.	WO	98/03516	A1	Pfizer Inc.	01-29-1998	
	298.	WO	98/30566	A1	Pfizer Inc.	07-16-1998	
	299.	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
	300.	WO	00/09485	A1	Pfizer Products Inc.	02-24-2000	
	301.	WO	00/09492	A1	Pfizer Products Inc.	02-24-2000	
	302.	WO	00/73294	A2	Pfizer Products Inc.	12-07-2000	
	303.	WO	01/12611	A1	Pfizer Products Inc.	02-22-2001	
	304.	WO	01/40216	A1	Pfizer Products Inc.	06-07-2001	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



FEE TRANSMITTAL

Application Number 09/857,994

Art Unit 1617

Filing Date October 5, 2001

Confirmation No. 4028

Inventor(s) John P. McKearn et al.

Attorney Docket Number PHA 2005 (3167/6Z/US)

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- ☒ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- ☐ Applicant claims small entity status.
2. ☒ Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

FEE CALCULATION

1. ☐ BASIC FILING FEE Subtotal (1) \$ _____
(Type: _____)
2. ☐ EXTRA CLAIM FEES Subtotal (2) \$ _____
Total Claims _____
Independent Claims _____
Multiple Dependent Claims _____
3. ☒ ADDITIONAL FEES Subtotal (3) \$ 180.00
 - ☐ Surcharge - late filing fee or oath
 - ☐ Surcharge - late provisional filing fee or cover sheet
 - ☐ Extension for reply within _____ month
 - ☐ Notice of Appeal
 - ☐ Filing a Brief in Support of an appeal
 - ☐ Request for ex parte Reexamination
 - ☐ Petitions to the Commissioner
 - ☒ Submission of Information Disclosure Statement
 - ☐ Recording each patent assignment per property
 - ☐ Request for Continued Examination
 - ☐ Other: _____

TOTAL AMOUNT OF PAYMENT \$ 180.00

Kathryn J. Doty, Reg. No. 40,593

February 18, 2004
Date

KJD/CDS/msc

Express Mail Label No. EV 416453092 US